Amtagvi

News

Iovance cuts staff on slower cell therapy sales growth

Iovance will slash 19% of its headcount in a restructuring that follows slower-than-expected sales growth for melanoma cell therapy Amtagvi.

News

New era for cell therapy as FDA OKs first for solid tumours

Iovance Biotherapeutics has carved out a piece of biotech history, becoming the first company to win FDA clearance for a cell therapy used to treat a solid tumour.

News

After setback, Rhythm gets good news on Imcivree from FDA

Rhythm Pharma has secured the first approval in the US for a drug to treat hypothalamic obesity.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Sales & Marketing

Using AI-driven synthetic personas to take your insights fur...

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.

Editor's Picks